• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Bio-Techne Corp (Amendment)

    2/9/22 3:33:30 PM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TECH alert in real time by email
    SC 13G/A 1 tv0417-biotechnecorp.htm SCHEDULE 13G/A biotechnecorp

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 10)*

    Name of issuer:  Bio-Techne Corp.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  09073M104

    Date of Event Which Requires Filing of this Statement: December 31, 2021

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  09073M104

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    66,439

    7.  SOLE DISPOSITIVE POWER

    4,263,811

    8.  SHARED DISPOSITIVE POWER

    162,827

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,426,638

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    11.27%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Bio-Techne Corp.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    614 McKinley Place NE
    Minneapolis, MN 55413-2610

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    09073M104

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 9, 2022

    By /s/ Christine M. Buchanan
    Name: Christine M. Buchanan
    Title:  Principal

    Get the next $TECH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TECH

    DatePrice TargetRatingAnalyst
    9/3/2025$73.00Sector Perform → Outperform
    RBC Capital Mkts
    8/21/2025$70.00Neutral → Buy
    Citigroup
    7/22/2025$65.00Overweight
    Stephens
    7/9/2025$65.00Buy
    TD Cowen
    5/30/2025$59.00Overweight
    Wells Fargo
    4/9/2025Overweight → Sector Weight
    KeyBanc Capital Markets
    3/18/2025$75.00Outperform
    Evercore ISI
    2/19/2025$88.00 → $68.00Outperform → Neutral
    Robert W. Baird
    More analyst ratings

    $TECH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bio-Techne upgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts upgraded Bio-Techne from Sector Perform to Outperform and set a new price target of $73.00

    9/3/25 8:14:45 AM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bio-Techne upgraded by Citigroup with a new price target

    Citigroup upgraded Bio-Techne from Neutral to Buy and set a new price target of $70.00

    8/21/25 8:10:31 AM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Stephens resumed coverage on Bio-Techne with a new price target

    Stephens resumed coverage of Bio-Techne with a rating of Overweight and set a new price target of $65.00

    7/22/25 7:51:31 AM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TECH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Kelderman Kim covered exercise/tax liability with 2,303 shares, decreasing direct ownership by 5% to 48,665 units (SEC Form 4)

    4 - BIO-TECHNE Corp (0000842023) (Issuer)

    11/5/25 4:46:58 PM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CFO Hippel James converted options into 24,704 shares and covered exercise/tax liability with 11,865 shares, increasing direct ownership by 10% to 142,722 units (SEC Form 4)

    4 - BIO-TECHNE Corp (0000842023) (Issuer)

    11/5/25 4:46:41 PM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    PRESIDENT, PROTEIN SCIENCES Geist William converted options into 9,911 shares and covered exercise/tax liability with 4,520 shares, increasing direct ownership by 36% to 20,503 units (SEC Form 4)

    4 - BIO-TECHNE Corp (0000842023) (Issuer)

    11/5/25 4:46:25 PM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TECH
    SEC Filings

    View All

    SEC Form 10-Q filed by Bio-Techne Corp

    10-Q - BIO-TECHNE Corp (0000842023) (Filer)

    11/5/25 4:31:36 PM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bio-Techne Corp filed SEC Form 8-K: Results of Operations and Financial Condition, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

    8-K - BIO-TECHNE Corp (0000842023) (Filer)

    11/5/25 6:31:03 AM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEFA14A filed by Bio-Techne Corp

    DEFA14A - BIO-TECHNE Corp (0000842023) (Filer)

    9/19/25 7:01:32 AM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TECH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bio-Techne Releases First Quarter Fiscal 2026 Results

    MINNEAPOLIS, Nov. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the first quarter ended September 30, 2025. First Quarter FY2026 Highlights First quarter reported and organic revenue decreased 1% to $286.6 million.GAAP earnings per share (EPS) was $0.24 versus $0.21 for first quarter 2025. Delivered adjusted EPS of $0.42 compared to $0.42 for first quarter 2025.Completed the divestiture of the Exosome Diagnostics business including the ExoDx Prostate test (EPI) as the Company emphasizes investment and commercial priorities on non-CLIA based product lines in their growth pillars. Ongoing productivity and cost containment initiatives led

    11/5/25 6:30:00 AM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BIO-TECHNE DECLARES DIVIDEND

    MINNEAPOLIS, Nov. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended September 30, 2025. The quarterly dividend will be payable November 28, 2025, to all common shareholders of record on November 17, 2025. Future cash dividends will be considered by the Board of Directors on a quarterly basis. Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of s

    11/5/25 6:30:00 AM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AI-Powered Spatial Biology Workflow from Bio-Techne and Nucleai Enables Predictive Biomarker Discovery in Melanoma Patients

    Clinical trial data demonstrates how Bio-Techne's spatial biology technology and Nucleai's AI-powered multimodal platforms can identify predictive biomarkers in immunotherapy and targeted therapy-treated melanoma patients. Bio-Techne's COMET™ platform and Nucleai's multimodal spatial operating system profiled 42 biopsies, revealing immune cell interactions linked to clinical outcomes. Study selected by the scientific committee as one of the top 150 abstracts from over 1,200 submissions at SITC 2025.MINNEAPOLIS and TEL AVIV, Israel, Nov. 4, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH), a global provider of life science tools, reagents, and diagnostic products, and Nucleai, a lead

    11/4/25 9:01:00 AM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TECH
    Financials

    Live finance-specific insights

    View All

    Bio-Techne Releases First Quarter Fiscal 2026 Results

    MINNEAPOLIS, Nov. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the first quarter ended September 30, 2025. First Quarter FY2026 Highlights First quarter reported and organic revenue decreased 1% to $286.6 million.GAAP earnings per share (EPS) was $0.24 versus $0.21 for first quarter 2025. Delivered adjusted EPS of $0.42 compared to $0.42 for first quarter 2025.Completed the divestiture of the Exosome Diagnostics business including the ExoDx Prostate test (EPI) as the Company emphasizes investment and commercial priorities on non-CLIA based product lines in their growth pillars. Ongoing productivity and cost containment initiatives led

    11/5/25 6:30:00 AM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BIO-TECHNE DECLARES DIVIDEND

    MINNEAPOLIS, Nov. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended September 30, 2025. The quarterly dividend will be payable November 28, 2025, to all common shareholders of record on November 17, 2025. Future cash dividends will be considered by the Board of Directors on a quarterly basis. Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of s

    11/5/25 6:30:00 AM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bio-Techne to Host Conference Call on November 5, 2025, to Announce First Quarter Fiscal 2026 Financial Results

    MINNEAPOLIS, Oct. 15, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call and webcast on Wednesday, November 5, 2025, at 8:00 a.m. CST to review its first quarter fiscal 2026 financial results. Access to the discussion may be obtained as follows: Time:                    8:00 a.m. CST Date:                      November 5, 2025 Dial-in:    1-800-274-8461 or 1-203-518-9814 (for international callers) Conference ID:      TECHQ1 Webcast:                https://investors.bio-techne.com/ir-calendar A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-

    10/15/25 7:00:00 AM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TECH
    Leadership Updates

    Live Leadership Updates

    View All

    Bio-Techne Appoints Dr. Amy E. Herr to Board of Directors

    MINNEAPOLIS, Feb. 4, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the appointment of Amy E. Herr, Ph.D. to serve as an independent director on the Company's Board of Directors beginning on February 1, 2025. Dr. Herr will serve on the Science & Technology Committee of the Board of Directors. Dr. Herr is a Chancellor's Professor of Bioengineering at the University of California, Berkeley. Dr. Herr also currently serves as the Vice President of the Chan Zuckerberg Biohub Network, a group of nonprofit research institutes established to create tools required to understand the mysteries of the cell to ultimately cure, prevent, and manage human disease. Since joining th

    2/4/25 7:00:00 AM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BIO-TECHNE APPOINTS DR. JUDITH KLIMOVSKY TO BOARD OF DIRECTORS

    MINNEAPOLIS, April 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the appointment of Dr. Judith Klimovsky to serve as an independent director on the Company's Board of Directors, April 24, 2024. Dr. Klimovsky will serve as a member of the Science and Technology Committee. Following the appointment, the board of Bio-Techne will be temporarily comprised of eleven directors, ten of whom are independent. Dr. Klimovsky is currently the Executive Vice President and Chief Development Officer at Genmab, an international biotechnology company specialized in the creation and development of antibody therapeutics. Before joining Genmab in 2017, Dr. Klimovsky held various s

    4/30/24 7:00:00 AM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BIO-TECHNE ANNOUNCES APPOINTMENT OF MATTHEW F. McMANUS AS PRESIDENT, DIAGNOSTICS AND GENOMICS SEGMENT

    MINNEAPOLIS, Jan. 5, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced Matthew F. McManus has been appointed President, Diagnostics and Genomics Segment, effective January 8, 2024. Dr. McManus succeeds Kim Kelderman, who will become Bio-Techne's Chief Executive Officer effective February 1, 2024. Dr. McManus has over two decades of experience as a senior life sciences leader, most recently serving as Executive Vice President and Chief Operating Officer for Azenta, where he was responsible for Life Sciences Products, Services, and all commercial operations of the business. Previously, Dr. McManus was Senior Vice President and General Manager of Bio-Techne's Molecular D

    1/5/24 7:00:00 AM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TECH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Bio-Techne Corp

    SC 13G - BIO-TECHNE Corp (0000842023) (Subject)

    11/14/24 1:22:36 PM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Bio-Techne Corp (Amendment)

    SC 13G/A - BIO-TECHNE Corp (0000842023) (Subject)

    2/13/24 5:00:46 PM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Bio-Techne Corp (Amendment)

    SC 13G/A - BIO-TECHNE Corp (0000842023) (Subject)

    2/9/23 11:12:40 AM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care